Skip to Content

Join the 'Non-Small Cell Lung Cancer' group to help and get support from people like you.

Non-Small Cell Lung Cancer News

Related terms: Cancer, Lung, Non-Small Cell, Lung Cancer, Non-Small Cell, NSCLC

Many With Advanced Lung Cancer Don't Get Treatments That Might Help

Posted 11 hours ago by Drugs.com

FRIDAY, Jan. 20, 2017 – Many U.S. patients with late-stage lung cancer do not receive treatments that could prolong their lives, a new study finds. Researchers at the University of California, Davis Comprehensive Cancer Center analyzed 1998-2012 data from the U.S. National Cancer Database. They found that more than one in every five patients with non-small cell lung cancer (NSCLC) – by far the leading form of the disease – did not undergo any treatment. That included chemotherapy, radiotherapy or surgery, the researchers said. Many of the untreated patients were women, elderly, minorities, low-income and uninsured, according to the research team. The researchers found that the number of untreated patients with late-stage NSCLC even rose slightly during the study period. The reasons why some patients went untreated remain unclear, the researchers said. "We were able to identify a ... Read more

Related support groups: Surgery, Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Malignant Pleural Effusion, Bronchogenic Carcinoma, Merkel Cell Carcinoma

Delaying Chemo After Lung Cancer Surgery? Better Late Than Never

Posted 15 days ago by Drugs.com

FRIDAY, Jan. 6, 2017 – Lung cancer chemotherapy that's been delayed due to slow recovery from surgery can still provide real benefit to patients, a new study suggests. The study involved thousands of patients with non-small-cell lung cancers (NSCLC), which comprise about 90 percent of all lung tumors. Lung cancer remains the leading cancer killer in the United States. As the study authors explained, chemotherapy is a standard part of treatment for people who've already had surgery to treat tumors that are larger than 4 centimeters (about 1.5 inches) or that have spread to the lymph nodes. Typically, this post-surgical chemotherapy begins within six weeks of the surgery. However, not all patients are able to tolerate chemotherapy so quickly after their operation, including those who develop surgical complications. So, a team led by Dr. Daniel Boffa, from the Yale School of Medicine, ... Read more

Related support groups: Lung Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Bronchogenic Carcinoma

Immune-Focused Drug Shows Promise Against Lung Cancer

Posted 13 Dec 2016 by Drugs.com

TUESDAY, Dec. 13, 2016 – An immunotherapy drug called Tecentriq (atezolizumab) extended the survival of lung cancer patients for several months longer than chemotherapy and caused fewer side effects, according to a new study. The findings are from an early analysis of 850 patients with non-small cell lung cancer in a phase 3 trial funded by the drug's makers. According to the American Cancer Society, non-small cell lung cancer is the major form of the disease, comprising up to 85 percent of cases. Lung cancer remains the leading cancer killer in the United States, with more than 158,000 people expected to die from the disease this year. The patients in the new trial had run out of treatment options. They received either Tecentriq or the chemotherapy drug docetaxel – the standard treatment for this type of cancer. According to a team led by Dr. David Gandara of the University of ... Read more

Related support groups: Lung Cancer, Non-Small Cell Lung Cancer, Tecentriq, Atezolizumab

It's Never Too Late to Stop Smoking

Posted 30 Nov 2016 by Drugs.com

WEDNESDAY, Nov. 30, 2016 – You're never too old to reap the health benefits of quitting smoking, a new study finds. "Even participants who quit smoking as recently as in their 60s were 23 percent less likely to die during follow-up than those who continued to smoke into their 70s," said lead researcher Sarah Nash, who conducted the study while at the U.S. National Cancer Institute. In addition, the age at which you start smoking can have an impact on longevity, the researchers found. "This study confirms that age at smoking initiation and cessation, both key components of smoking duration, continue to be important predictors of mortality in U.S. adults over age 70," Nash said. "It also underscores the importance of measures to prevent initiation, as well as encourage cessation, for all smokers," she added. Nash is currently with the Alaska Native Epidemiology Center at the Alaska ... Read more

Related support groups: Cancer, Smoking, Smoking Cessation, Lung Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer, Stomach Cancer, Head and Neck Cancer

Smoking Plus Diabetes a Very Deadly Mix

Posted 22 Nov 2016 by Drugs.com

TUESDAY, Nov. 22, 2016 – While smoking is tough enough on health, adding in diabetes boosts the risk of an early death even more, new research confirms. Heavy smokers who also have diabetes are at twice the risk of an early death compared to smokers without the blood sugar disease, the study found. "Smoking is bad for all, but even more in those with diabetes," said Dr. Joel Zonszein, director of the Clinical Diabetes Center at Montefiore Medical Center in New York City. He reviewed the new findings. The study was conducted by researchers at the University of Colorado, Denver, and involved data on more than 53,000 Americans who were either current or former heavy smokers. The overall risk of an early death was roughly double if the smoker had diabetes, the researchers reported. Overall, almost 13 percent of smokers with diabetes died during the seven-year study period, compared with ... Read more

Related support groups: Diabetes, Type 2, Smoking, Smoking Cessation, Diabetes, Type 1, Diabetic Neuropathy, Insulin Resistance, Diabetic Nerve Damage, Lung Cancer, Non-Small Cell Lung Cancer, Pre-Diabetes, Abnormal Glucose Tolerance, Intravenous Insulin Drip

Smoking Wreaks Genetic Havoc on Lungs, Study Warns

Posted 4 Nov 2016 by Drugs.com

FRIDAY, Nov. 4, 2016 – Smoking is linked to significant genetic damage in the lungs and other organs of the body, according to new research. "This study offers fresh insights into how tobacco smoke causes cancer," said co-lead author Ludmil Alexandrov, the Oppenheimer Fellow at Los Alamos National Laboratory in New Mexico. "Our analysis demonstrates that tobacco smoking causes mutations that lead to cancer by multiple distinct mechanisms," he said in a Los Alamos news release. "Tobacco smoking damages DNA in organs directly exposed to smoke as well as speeds up a mutational cellular clock in organs that are both directly and indirectly exposed to smoke." In the study, researchers from Los Alamos, the Wellcome Trust Sanger Institute in England and other institutions analyzed more than 5,000 cancer tumors from smokers and nonsmokers. Cancer is caused by mutations in the DNA of a cell, ... Read more

Related support groups: Smoking, Smoking Cessation, Lung Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Diagnosis and Investigation, Bronchogenic Carcinoma

FDA Approves Merck’s Keytruda (pembrolizumab) for First-Line Treatment of Certain Patients with Metastatic Non-Small Cell Lung Cancer

Posted 25 Oct 2016 by Drugs.com

KENILWORTH, N.J.--(BUSINESS WIRE) October 24, 2016 --Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab), the company’s anti-PD-1 (programmed death receptor-1) therapy, for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (tumor proportion score [TPS] of 50 percent or more) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. With this new indication, Keytruda is now the only anti-PD-1 therapy to be approved in the first-line treatment setting for these patients. In addition, the FDA approved a labeling update to include data from KEYNOTE-010 in the second-line or greater treatment setting for patients with metastatic NSCLC whose tumors express PD-L1 (TPS of ... Read more

Related support groups: Lung Cancer, Non-Small Cell Lung Cancer, Keytruda, Pembrolizumab

FDA Approves Genentech’s Cancer Immunotherapy Tecentriq (Atezolizumab) for People with a Specific Type of Metastatic Lung Cancer

Posted 19 Oct 2016 by Drugs.com

South San Francisco, CA – October 18, 2016 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq (atezolizumab) for the treatment of people with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy, and have progressed on an appropriate FDA-approved targeted therapy if their tumor has EGFR or ALK gene abnormalities. This approval is based on results from the randomized Phase III OAK and Phase II POPLAR studies. The largest study, OAK, showed that Tecentriq helped people in the overall study population live a median of 13.8 months, 4.2 months longer than those treated with docetaxel chemotherapy (median overall survival [OS]: 13.8 vs. 9.6 months; HR = 0.74, 95% CI: 0.63, 0.87). The study enrolled people ... Read more

Related support groups: Lung Cancer, Non-Small Cell Lung Cancer, Tecentriq, Atezolizumab

New Type of Radiation Treatment May Up Survival for Older Lung Cancer Patients

Posted 26 Sep 2016 by Drugs.com

MONDAY, Sept. 26, 2016 – Cutting-edge radiation therapy seems to provide a significant survival advantage for older people with early stage lung cancer who aren't strong enough for surgery, a pair of new studies suggests. The therapy is called stereotactic body radiation therapy (SBRT) and it's been available for about a decade. The first study reviewed national cancer data and found that survival rates for older lung cancer patients treated with radiation therapy increased dramatically between 2004 and 2012. Those are the years during which SBRT use became widespread in the United States, said lead researcher Dr. Andrew Farach, a radiation oncologist at Houston Methodist Hospital. A second study based on Veterans Affairs cancer treatment data appears to corroborate the national findings, directly linking increased use of SBRT with improved survival rates in elderly patients. Farach ... Read more

Related support groups: Surgery, Lung Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, History - Radiation Therapy, Bronchogenic Carcinoma

More Cancer Patients Gaining From Immune-Based Treatments

Posted 20 Sep 2016 by Drugs.com

TUESDAY, Sept. 20, 2016 – A leading cancer group says more Americans are benefiting from immunotherapy – a relatively new treatment approach that helps the immune system target and destroy cancer cells. "The promise of immunotherapy for cancer therapy has never been greater, and the opportunity to make significant progress in this critical area is real," said Dr. Nancy Davidson, president of the American Association for Cancer Research (AACR). The AACR issued the news on immunotherapy as part of its 2016 Cancer Progress Report. As the group explained, more types of cancer are being successfully treated with immunotherapy. This treatment involves adding new cancer-fighting cells to the body or adding new elements, such as antibodies and proteins, to help the immune system fight cancer. In August 2015, one class of immunotherapy drugs – called checkpoint inhibitors – was approved for ... Read more

Related support groups: Lung Cancer, Non-Small Cell Lung Cancer, Melanoma, Opdivo, Bladder Cancer, Melanoma - Metastatic, Head and Neck Cancer, Hodgkin's Lymphoma, Keytruda, Tecentriq, Nivolumab, Pembrolizumab, Atezolizumab

14 Genes That May Affect Cancer Treatment

Posted 31 Aug 2016 by Drugs.com

WEDNESDAY, Aug. 31, 2016 – Researchers say they've identified 14 genes that may help determine whether a cancer treatment could help a patient. The researchers also say the findings suggest it could be possible to help people avoid unnecessary cancer treatments that won't likely benefit them. "The history of cancer treatment is filled with overreaction," said principal investigator Gary Karpen, a senior scientist at the U.S. Department of Energy's Lawrence Berkeley National Laboratory in Berkeley, Calif. "It is part of the ethics of cancer treatment to err on the side of overtreatment, but these treatments have serious side effects associated with them. For some people, it may be causing more trouble than if the growth was left untreated," Karpen said in a Berkeley Lab release. However, there has not been a reliable way to determine which early stage cancer patients will respond to ... Read more

Related support groups: Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Diagnosis and Investigation, Bronchogenic Carcinoma

Smog May Shorten Lives of Lung Cancer Patients

Posted 5 Aug 2016 by Drugs.com

FRIDAY, Aug. 5, 2016 – Air pollution may shorten the lives of lung cancer patients, a new study suggests. Researchers led by Sandrah Eckel, who's with the department of preventive medicine at the University of Southern California in Los Angeles, analyzed data from more than 352,000 people in California who were diagnosed with lung cancer between 1988 and 2009. Higher exposure to the pollutants nitrogen dioxide, ozone and airborne particles was associated with an increased risk of early death. The association was strongest in patients with early stage disease, particularly adenocarcinoma, which accounts for 80 percent of lung cancer cases, the researchers said. Early stage patients with greater exposure to pollutants survived on average 2.4 years compared to 5.7 years for those with low exposure, the study found. The study was published online Aug. 4 in the journal Thorax. Since this ... Read more

Related support groups: Lung Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Bronchogenic Carcinoma

New Guidelines Issued for Cancer Patients' Post-Treatment Pain

Posted 29 Jul 2016 by Drugs.com

FRIDAY, July 29, 2016 – More people are surviving cancer, but many are left with persistent pain after treatment. New guidelines from the American Society of Clinical Oncology (ASCO) recommend that doctors routinely screen for such pain. The guidelines also advise doctors to consider the use of non-traditional treatments for pain. These include hypnosis, meditation and medical marijuana where it's legal. ASCO also cautioned doctors to assess patients' risk for overuse of opioid painkillers. "Many oncologists and primary care physicians are not trained to recognize or treat long-term pain associated with cancer," guideline panel co-chair Judith Paice said in an ASCO news release. "This guideline will help clinicians identify pain early and develop comprehensive treatment plans, using a broad range of approaches," she said. Advances in cancer diagnosis and treatment have led to a record ... Read more

Related support groups: Pain, Suboxone, Oxycodone, Hydrocodone, Methadone, Percocet, Tramadol, Cancer, OxyContin, Vicodin, Norco, Fentanyl, Morphine, Codeine, Lortab, Tylenol, Chronic Pain, Opana, Ibuprofen, Naproxen

U.S. Cancer Survivors Living Longer

Posted 1 Jul 2016 by Drugs.com

FRIDAY, July 1, 2016 – As the American population ages, more older adults will survive cancer and live with other chronic conditions that will burden the health care system, U.S. government health officials report. "Increasingly, we are seeing the impact of an aging population – fueled by maturing baby boomers – on major diseases, including cancer," said lead researcher Shirley Bluethmann, a cancer prevention fellow at the U.S. National Cancer Institute. In 2016, nearly 62 percent of almost 16 million cancer survivors are aged 65 or older, the researchers said. By 2040, an estimated 73 percent of 26 million cancer survivors will be 65 or older. "This steady and dramatic growth will affect the health care system, and so is sometimes referred to as the 'silver tsunami,' " Bluethmann said. "It not only has implications for older people who are at higher risk for cancer, it also means ... Read more

Related support groups: Cancer, Breast Cancer, Lung Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer, Melanoma, Skin Cancer, Ovarian Cancer, Melanoma - Metastatic, Solid Tumors

Video May Aid End-of-Life Decision-Making

Posted 30 Jun 2016 by Drugs.com

THURSDAY, June 30, 2016 – Watching a video about end-of-life care options may help patients with advanced heart failure choose the approach best for them, a new study finds. The choices include comfort-focused care versus more invasive care that could extend their days. "Because the course of heart failure is uncertain, in part because of improved therapies, doctors may be reluctant to initiate a conversation with their patients about advance care planning," said study lead author Dr. Areej El-Jawahri. She is director of the bone marrow transplant survivorship program at Massachusetts General Hospital Cancer Center in Boston, and a member of the Video Images of Disease for Ethical Outcomes Consortium, which develops videos for decision-making support. Heart failure means the heart struggles to provide the body with enough blood to remain healthy. People with advanced heart failure tend ... Read more

Related support groups: Cancer, Lung Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer, Melanoma, Ovarian Cancer, Melanoma - Metastatic, Breast Cancer - Palliative

Page 1 2 3 4 5 6 7 8 9 10 Next

Ask a Question

Further Information

Related Condition Support Groups

Lung Cancer

Related Drug Support Groups

methotrexate, Avastin, Tarceva, Taxol, Opdivo, Taxotere, Xalkori, cisplatin, cyclophosphamide, view more... paclitaxel, Iressa, Keytruda, capecitabine, Gemzar, gemcitabine, Alimta, nivolumab, Tecentriq, docetaxel, erlotinib, Cyramza, Abraxane, bevacizumab, gefitinib, pembrolizumab, ramucirumab, Gilotrif, afatinib, Navelbine, vinorelbine, amifostine, Platinol, crizotinib, Methotrexate LPF Sodium, osimertinib, pemetrexed, Alecensa, Trexall, Tagrisso, cetuximab, alectinib, Zykadia, Portrazza, Ethyol, necitumumab, ceritinib, porfimer, paclitaxel protein-bound, atezolizumab, Onxol, Platinol-AQ, Folex PFS, Photofrin, Docefrez